Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy
|ClinicalTrials.gov Identifier: NCT00509574|
Recruitment Status : Unknown
Verified November 2010 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : July 31, 2007
Last Update Posted : December 13, 2010
|Condition or disease||Phase|
|Statins, HMG-CoA Single Nucleotide Polymorphism||Phase 4|
Hyperlipidemic patients are retrospectively screened from 2006/1/1 to 2006/12/31. The patient is included if he or she had been receiving atorvastatin or rosuvastatin for at least 3 months and did not receive other lipid-lowering medications 4 weeks before starting atorvastatin or rosuvastatin. Genomic DNA was collected from the blood sample of each patient using genomic DNA purification kit. The single nucleotide polymorphisms (SNPs) were determined afterward.
The correlation between response of statin therapy, defined as changes in lipid profiles including triglyceride, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol, and SNPs examined.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy|
|Study Start Date :||March 2007|
|Estimated Study Completion Date :||February 2010|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00509574
|Contact: Tzung-Dau Wang, MD, PhD||886-2-2312-3456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Principal Investigator:||Tzung-Dau Wang, MD, PhD||Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital|